WuXi STA to build new R&D center in Shanghai

1 May 2018

Integrated one-site solution for partners to push forward innovative APIs and advanced intermediates from preclinical to commercial stage.

STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center. The new facility will further strengthen WuXi STA’s global leading pharmaceutical development and manufacturing platform, enabling drug developers to accelerate their projects from preclinical to commercial stage.

WuXi STA to build new R&D center in Shanghai

WuXi STA has already established an industry leading process development platform with over 1,000 scientists and five sites located in China and the US. The company’s Jinshan site currently focuses on manufacturing innovative APIs and advanced intermediates from kilo to metric ton scale. The site has been approved by multiple international regulatory agencies, including the FDA.

The new R&D center will be located next to the existing Jinshan drug substance manufacturing site, adding more than 30,000 m2 of laboratory space and 500 scientists. Upon completion, the expanded Jinshan campus will be able to offer an integrated one-site solution for partners to push forward innovative APIs and advanced intermediates — from preclinical and clinical development through to global commercial launch. The new campus will also provide access to industry-leading technology platforms such as flow chemistry, biocatalysis, and high potency from laboratory to commercial scale.

Shanghai Jinshan District has enjoyed sustained economic growth in recent years, via its strategic focus on “smart manufacturing”, and has attracted many biotechnology and pharmaceutical companies including WuXi STA. “This new R&D center in Caojing Town, Jinshan is a result of the long-term ‘win-win’ collaboration between the Jinshan government and WuXi STA. The project will further strengthen the life science industry ecosystem in Jinshan District,” said Mr Quanquan Zhang, Vice Governor of Jinshan.

“The new R&D center is a reflection of our commitment to better serve customers worldwide and support growth in the local economy, as well as the biopharmaceutical ecosystem in Jinshan,” said Dr Minzhang Chen, CEO of WuXi STA. “As we continuously strengthen the capability and capacity of our platform, we will enable more global partners to shorten development timelines and lower the cost of new drug development, improving the lives of people around the world.”

Read More

Related news

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more 
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

18 Jul 2018

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Read more 
New screening company exploits the latest advances in microfluidics and 3D culture

New screening company exploits the latest advances in microfluidics and 3D culture

19 Jul 2018

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Read more 
Natural lipid acts as potent anti-inflammatory

Natural lipid acts as potent anti-inflammatory

10 Jul 2018

Scientists see therapeutic potential against bacteria, viruses.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more 
Follicum develops new direct-to-scalp formulation

Follicum develops new direct-to-scalp formulation

27 Jun 2018

The topical treatment for hair loss boasts a 'commercial' formulation.

Read more 
Collaboration to provide GMP-based services

Collaboration to provide GMP-based services

19 Jun 2018

Researchers to benefit by receiving a rapid and cost-effective scaled supply of new compounds.

Read more 
Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs

Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs

5 Jun 2018

TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.

Read more